Scribe Therapeutics, Inc.
SCTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001853921
In the last 90 days, Scribe Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Holders of 5% or more of SCTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Scribe Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 13D | 16.37%3.09M shares | New | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| Ra Capital Management, L.P. | 13G | 9.60%1.80M shares | New | Aug 3, 20261 filing | Aug 3, 2026 | SEC |
| Eli Lilly & Co | 13D | 7.30%1.39M shares | New | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| OrbiMed Advisors LLC | 13D | 7.20%1.35M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Scribe Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 3, 20264:37 PM ET | Ra Capital Management, L.P.and 3 others | 13G | 9.60%1.80M shares | New | Jul 27, 2026 | SEC |
| Jul 30, 20269:30 PM ET | Avoro Capital Advisors LLCand 2 others | 13D | 16.37%3.09M shares | New | Jul 24, 2026 | SEC |
| Jul 30, 20264:39 PM ET | Eli Lilly & Co | 13D | 7.30%1.39M shares | New | Jul 23, 2026 | SEC |
| Jul 29, 20266:42 PM ET | OrbiMed Advisors LLCand 1 other | 13D | 7.20%1.35M shares | New | Jul 27, 2026 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Scribe Therapeutics, Inc. shares.
No Form 144 notices for Scribe Therapeutics, Inc. are on file.